Stem Cell Transplantation for Newly Diagnosed M/M
IMS 2022 Final Analysis of the GRIFFIN Trial: Daratumumab + Lenalidomide, Bortezomib, & Dexamethasone for Transplant-Eligible NDMM
Login to view comments.
Click here to Login
Stem Cell Transplantation for Newly Diagnosed M/M